Mylan Inc. (MYL) has been upgraded today by the research analysts at investment firm Argus which adjusted MYL from a “hold” rating to “buy.” Argus also set a price target for MYL at $29 dollars. MYL is up during intraday trading.
Mylan is slated to release their next earnings report on July 28th, 2011 and is estimated to post EPS of 45 cents. Their last earnings report was released on May 3rd, 2011 and announced EPS of 44 cents with revenue totaling 1.436 billion which was up 12.4 % year to year. MYL is currently trading above its 50 & 200-day moving averages and 2011 is an up year for the company.
Mylan Inc. maintains one of the industry’s broadest product portfolios supported by a robust product pipeline and a vertically integrated active pharmaceutical ingredient operation and runs a specialty business focused on respiratory, allergy and psychiatric therapies. The company has market capitalization of $10,227,000,000 and 437,057,000 shares outstanding. MYL has a 52-week high of $25.46 with the low being $16.55 dollars.